08/04/2026
A new oral GLP-1 medication has just launched in the United States.
For many patients, this represents another important step forward in the treatment of obesity and metabolic disease.
Unlike the injectable GLP-1 medications many people are familiar with, this new therapy is a tablet taken once daily. It works on the same appetite and satiety pathways but is chemically different: it’s a non-peptide small-molecule GLP-1, which means it can be absorbed orally rather than requiring an injection.
In clinical trials, patients taking this oral GLP-1 therapy lost around 11% of their body weight on average.
While this is not as powerful as the injectable GLP-1 medications, it is still very clinically meaningful weight loss and may suit many patients who prefer tablets or who require a different treatment approach.
Why this matters:
• More treatment options for patients
• A potential alternative for people who prefer not to inject medications
• Another tool clinicians can use as part of structured medical weight management
Importantly, medications are just one part of treatment. Sustainable results come from a comprehensive approach including:
• medical assessment
• nutrition support
• metabolic health optimisation
• behaviour and lifestyle change
The medication has just launched in the United States and is currently progressing through regulatory approval in Australia, with availability here likely around 2027.
At MedSurg Weight Loss, we closely follow emerging treatments so we can continue offering patients evidence-based care and the latest therapeutic options as they become available.
📍 Hawthorne, Brisbane
🔗 Book via the link in bio
